Parkinson’s research on NAD has mainly investigated oral nicotinamide riboside, or NR. Those studies should not be presented as proof that an NAD+ infusion slows Parkinson’s disease.
Early trials explored whether NR could alter NAD biology and be tolerated under monitoring. They have not established a reason to replace prescribed Parkinson’s treatment with a supplement or a wellness-clinic service.
Early NR studies support further investigation. Short safety trials and biomarker changes do not establish slower disease progression.
What was NADPARK designed to find out?
The 2022 NADPARK phase I trial enrolled 30 newly diagnosed, untreated patients for 30 days. Oral NR produced a variable increase in brain NAD and changes in related metabolic measurements. Some findings were associated with mild clinical improvement. The study’s small size and short duration make this an early biological signal, not proof of durable symptom relief or disease modification.
What did NR-SAFE contribute?
The 2023 NR-SAFE trial randomized 20 people with Parkinson’s to NR or placebo for four weeks. Its main purpose was short-term safety at a higher research exposure. The paper reported a modest serum homocysteine increase and did not find depletion of the measured methyl-group pool. Clinical observations in such a small safety study cannot establish long-term benefit. Research amounts used under monitoring are not self-treatment instructions.
What question does the larger study ask?
The investigators’ NOPARK study page describes a longer randomized comparison using a Parkinson’s clinical rating scale over 52 weeks. A protocol states the question and methods; it is not a positive result. In the primary sources checked for this article, we did not verify a published final NOPARK efficacy report. Claims about its outcome should point to the actual results publication.
Why more NAD is not the same as neuroprotection
A biological measurement can show that an intervention reached a target without showing that people function better for longer. Disease modification requires evidence about progression over an appropriate period, with a meaningful comparison group. See brain and memory claims for related distinctions across different neurological conditions. Alzheimer’s, Parkinson’s, and everyday concentration complaints are not interchangeable populations.
How to discuss NR with a treating specialist
Bring the specific product label, the trial citation, and your current medicine list. Ask whether the research applies to your disease stage, what uncertainties remain, and whether a monitored trial is available. Do not change Parkinson’s medicines or add high research amounts based on a blog summary. A registered study and a commercial “brain health” package offer different kinds of oversight.
Questions for a clinic advertising NAD for Parkinson’s
Ask whether the cited study tested oral NR or the route the clinic sells, and whether the main endpoint was safety, a biomarker, or clinical progression. Also ask how adverse effects and medication questions are handled. Route comparisons and research-reading guidance can help you assess the answer.
Sources & reading notes
Primary sources checked September 18, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- Brakedal et al. (2022): NADPARK phase I trial 30 patients, 30 days, oral NR; early brain-NAD and metabolic findings do not establish slower progression.
- Berven et al. (2023): NR-SAFE Parkinson safety trial 20 participants, four weeks; short-term safety and metabolic observations, not long-term efficacy.
- Neuro-SysMed: NOPARK study description Investigator protocol and endpoint description; not a published efficacy result.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.